Danaher Corp (DHR) company profile
Close on Nov 13, 2026Market cap $163.94BP/E 38.1Yield –
About Danaher
Industrial Instruments For Measurement, Display, and Control, SIC 3823
Danaher is a science and technology innovator that develops products and services to advance human health. The company operates through more than fifteen operating companies divided into three primary segments: Biotechnology, Life Sciences, and Diagnostics. Biotechnology provides bioprocessing equipment, consumables, filtration technologies, and analytical tools used to research and manufacture biotherapeutics such as vaccines and gene therapies. Life Sciences supplies instruments, consumables, software, and filtration solutions, including mass spectrometers, microscopes, and custom nucleic acids, for genomic and cellular research. Diagnostics offers biomedical testing instruments, clinical lab systems, and diagnostic consumables to analyze bodily fluids, detect infections, and support medical treatment decisions. Its customers include biopharmaceutical companies, research institutions, clinical laboratories, hospitals, and physician practices.
The company maintains research, manufacturing, sales, distribution, service, and administrative facilities across approximately 50 countries, with primary manufacturing operations located in North America, Europe, Asia, and Australia. Danaher employs approximately 60,000 associates globally, with its workforce distributed across North America, Western Europe, and high-growth markets. The provided text does not state the location of the company's headquarters.
Summary of the business section of Danaher's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Danaher Corp
- Founded
- 1981
- Headquarters
- Washington, DC
- Address
- 2200 Pennsylvania Ave. N.W., Suite 800w 20037-1701
- Phone
- (202) 828-0850
- Website
- www.danaher.com
- Employees
- 60,000, Dec 31, 2025
- Industry
- Industrial Instruments For Measurement, Display, and Control
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Tysons, Virginia
Stock & identifiers
- Ticker
- DHR
- Exchange
- NYSE
- IPO date
- Dec 29, 1978
- Shares outstanding
- 704M, Oct 15, 2026
- Public float
- $125.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 14, 2010; 2-for-1, May 21, 2004; 2-for-1, Jun 1, 1998; 2-for-1, Jan 23, 1995; 2-for-1, Sep 9, 1987
- SEC CIK
- 313616
- CUSIP
- 235851102
- ISIN
- US2358511028
- FIGI
- BBG000BH3JF8
- Share class FIGI
- BBG001S5QGT0
- LEI
- S4BKK9OTCEWQ3YHPFM11
- EIN
- 59-1995548
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven M. Rales | Chairman, Director | 34,126,743 |
| Mitchell P. Rales | Chairman of Exec. Committee, Director | 27,006,637 |
| Rainer Blair | President & CEO, Director | 45,743 |
| Matthew McGrew | Executive Vice President | 22,968 |
| Gregory M. Milosevich | Executive Vice President | 22,367 |
| Christopher Bouda | VP, Chief Accounting Officer | 9,787 |
| Shashanka Muppaneni | SVP, Chief Strategy Officer | 5,901 |
| Heathre T. Moler | SVP, Chief HR Officer | 5,356 |
| Jonathan Leiken | SVP-Chief Legal Officer | 12,546 |
| Jose-Carlos Gutierrez-Ramos | SVP, Chief Science Officer | 32,495 |
| Montgomery Julie A. Sawyer | Executive Vice President | 22,221 |
| Christopher Paul Riley | Executive Vice President | 61,472 |
| Matthew E. Gugino | EVP & Chief Financial Officer | 11,744 |
| Georgeann Couchara | SVP, Human Resources | 8,291 |
| R. Bradley Gray | SVP Strategic Development | 14,463 |
| Brian W. Ellis | Senior Vice President | 14,994 |
| Daniel Raskas | SVP - Corporate Development | 10,524 |
| Elias A. Zerhouni | Director | 53,984 |
| A. Shane Sanders | Director | 5,914 |
| Linda Filler | Director | 49,600 |
| Feroz Dewan | Director | 4,686 |
| Raymond C. Stevens | Director | 13,728 |
| Alan G. Spoon | Director | 133,474 |
| Teri List | Director | 21,470 |
| Daniel L. Comas | Director | 179,651 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $23.80M | $17.34M | $9.19M | $119 | $148 |
| FY2024 Rainer Blair | $22.11M | $7.47M | $6.72M | $119 | $129 |
| FY2024 Thomas Joyce | $0 | $0 | $6.72M | $119 | $129 |
| FY2023 Rainer Blair | $20.90M | $5.21M | $7.10M | $119 | $126 |
| FY2023 Thomas Joyce | $0 | $0 | $7.10M | $119 | $126 |
| FY2022 | $20.20M | $190.30K | $6.64M | $120 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Rainer M. Blair President and CEO | $1.40M | $9.29M | $8.39M | $4.19M | $521.85K | $23.80M | +8% |
| Matthew R. McGrew Executive Vice President and CFO | $1.01M | $2.52M | $2.27M | $1.88M | $287.11K | $7.97M | +7% |
| Christopher P. Riley Executive Vice President | $848.00K | $4.43M | $4.29M | $1.59M | $100.19K | $11.26M | – |
| Julie Sawyer Montgomery Executive Vice President | $848.00K | $4.43M | $4.29M | $1.59M | $139.62K | $11.30M | – |
| Jose-Carlos Gutierrez-Ramos Senior Vice President and Chief Science Officer | $888.46K | $1.96M | $1.77M | $1.53M | $97.02K | $6.24M | -17% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had approximately 60,000 employees (whom we refer to as “associates”), of whom approximately 22,000 were employed in North America, 20,000 in Western Europe, 3,000 in other developed markets and 15,000 in high-growth markets.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?